My laboratory research explores alternative pre-mRNA splicing in prostate cancer (PCa) biology, and liquid biopsy-derived molecular biomarkers of treatment outcomes. My clinical research investigates chemo-preventative strategies to reduce low risk PCa progression, and surgical alternatives to cytotoxic chemotherapy for metastatic testicular cancer.
FOXA1 regulates alternative splicing in prostate cancer. Cell Rep (2022) 40(13):111404. PMID: 36170835
Androgen receptor burden and poor response to abiraterone or enzalutamide in TP53 wild-type metastatic castration-resistant prostate cancer. JAMA Oncol (2019) 5(7):1060-1062. PMID: 31046065
TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer. Clin Cancer Res (2019) 25(6):1766-1773. PMID: 30209161
Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis. Genome Medicine (2018) 10(1):85. PMID: 30458854
The effect of comorbidity on prostate cancer-specific mortality: A prospective observational study. J Clin Oncol (2017) 35(31):3566-3574. PMID: 28930493
My laboratory-based research programme explores a link between alternative pre-mRNA splicing (AS), a ubiquitous post-transcriptional gene regulatory mechanism, and prostate cancer (PCa) phenotypes. During AS, coding (exons) and non-coding (introns) regions of a gene are shuffled to create protein isoforms with different functions. AS is regulated by trans-acting RNA-binding proteins (RBPs), and tightly coupled to transcription. We are studying the link between dysregulation of transcriptional and intracellular signalling processes and AS, mediated by RBPs.
Our translational research examines how blood-derived liquid biopsy molecular biomarkers can be used to improve treatment outcomes for PCa patients. With NHS colleagues, we are investigating minimally-invasive surgical alternatives to chemotherapy for metastatic testicular cancer to reduce the therapy burden and toxicity. In collaboration with the Wolfson Institute of Preventative Medicine, we are exploring how minimally-toxic chemo-preventative strategies may reduce PCa progression on active surveillance.
Understanding and managing the cardiovascular risks of androgen deprivation therapy for prostate cancer Atalar K, Rajan P Nature Reviews Urology (2023) 20(7) 3-4
Retzius-sparing technique independently predicts early recovery of urinary continence after robot-assisted radical prostatectomy Kadhim H, Ang KM, Tan WS et al. Journal of Robotic Surgery (2022) 16(7) 1419-1426
Feasibility of aspirin and/or vitamin D3 for men with prostate cancer on active surveillance with Prolaris® testing. Dinneen E, Shaw GL, Kealy R et al. BJUI Compass (2022) 3(2) 458-465
FOXA1 regulates alternative splicing in prostate cancer Del Giudice M, Foster JG, Peirone S et al. Cell Reports (2022) 40(7)
Safety of androgen therapy in men with prostate cancer Rajan P, Tharakan T, Chen R Best Practice and Research: Clinical Endocrinology and Metabolism (2022) 36(7)
Management of stage II seminoma: a contemporary UK perspective Alifrangis C, Nicol DL, Shamash J et al. Scottish Medical Journal (2022) 67(7) 126-128
Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: the Testing Radical prostatectomy in men with prostate cancer and oligo-Metastases to the bone (TRoMbone) trial Sooriakumaran P, Wilson C, Rombach I et al. BJU International (2022) 130(7) 43-53
HNRNPA2B1 controls an unfolded protein response-related prognostic gene signature in prostate cancer Foster J, Gea E, Labiba M et al. (2022) (18)
171 Developing & Centralising a Nurse-Led Local Anaesthetic (La) Transperineal (Tp) Biopsy Service During Covid: A Success Story Winters D, Mehmi A, Odedra A et al. British Journal of Surgery (2022) 109(10) znac039.102
Health-related quality of life and treatment-related side-effects in patients who have been in remission from testicular cancer for 12-24 months Cazzaniga W, Pearce A, Tanabalan C et al. EUROPEAN UROLOGY (2022) 81(11) S850-S850